PL2585480T3 - Przeciwnowotworowe białko fuzyjne - Google Patents

Przeciwnowotworowe białko fuzyjne

Info

Publication number
PL2585480T3
PL2585480T3 PL11727457T PL11727457T PL2585480T3 PL 2585480 T3 PL2585480 T3 PL 2585480T3 PL 11727457 T PL11727457 T PL 11727457T PL 11727457 T PL11727457 T PL 11727457T PL 2585480 T3 PL2585480 T3 PL 2585480T3
Authority
PL
Poland
Prior art keywords
fusion protein
anticancer fusion
anticancer
protein
fusion
Prior art date
Application number
PL11727457T
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Maciej Zerek
Krzysztof Kazimierz Lemke
Original Assignee
Adamed Pharma Spolka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Pharma Spolka Akcyjna filed Critical Adamed Pharma Spolka Akcyjna
Publication of PL2585480T3 publication Critical patent/PL2585480T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11727457T 2010-06-25 2011-06-24 Przeciwnowotworowe białko fuzyjne PL2585480T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL391627A PL391627A1 (pl) 2010-06-25 2010-06-25 Przeciwnowotworowe białko fuzyjne
PCT/EP2011/060666 WO2011161260A1 (en) 2010-06-25 2011-06-24 Anticancer fusion protein
EP11727457.1A EP2585480B1 (en) 2010-06-25 2011-06-24 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
PL2585480T3 true PL2585480T3 (pl) 2015-05-29

Family

ID=44627460

Family Applications (2)

Application Number Title Priority Date Filing Date
PL391627A PL391627A1 (pl) 2010-06-25 2010-06-25 Przeciwnowotworowe białko fuzyjne
PL11727457T PL2585480T3 (pl) 2010-06-25 2011-06-24 Przeciwnowotworowe białko fuzyjne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL391627A PL391627A1 (pl) 2010-06-25 2010-06-25 Przeciwnowotworowe białko fuzyjne

Country Status (24)

Country Link
US (1) US9102759B2 (pl)
EP (1) EP2585480B1 (pl)
JP (1) JP5911481B2 (pl)
KR (1) KR101861872B1 (pl)
CN (1) CN102958940B (pl)
AU (1) AU2011268876B2 (pl)
BR (1) BR112012032708A2 (pl)
CA (1) CA2800841C (pl)
CY (1) CY1116099T1 (pl)
DK (1) DK2585480T5 (pl)
EA (1) EA023005B1 (pl)
ES (1) ES2531288T3 (pl)
HR (1) HRP20150241T1 (pl)
IL (1) IL223640A (pl)
MX (1) MX2012015246A (pl)
PH (1) PH12013500050A1 (pl)
PL (2) PL391627A1 (pl)
PT (1) PT2585480E (pl)
RS (1) RS53851B1 (pl)
SG (1) SG186439A1 (pl)
SI (1) SI2585480T1 (pl)
UA (1) UA111722C2 (pl)
WO (1) WO2011161260A1 (pl)
ZA (1) ZA201300677B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
ES2388020B1 (es) * 2011-03-10 2013-10-01 Universitat De Girona Proteínas recombinantes con efecto antitumoral.
PL394618A1 (pl) * 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
CN109535259A (zh) * 2012-12-05 2019-03-29 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
CN103255160A (zh) * 2013-05-06 2013-08-21 徐霞 重组人可溶性肿瘤坏死因子相关的凋亡诱导配体的制备方法
CN103524627A (zh) * 2013-10-14 2014-01-22 成都华创生物技术有限公司 一种增强trail抗肿瘤活性的双靶点融合蛋白
EP3114232A4 (en) * 2014-03-03 2017-08-09 Acharjee, Sujata Chimeric dystrophin-vsv-g-protein to treat dystrophinopathies
BR102014031185A8 (pt) * 2014-12-12 2021-05-04 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN105985445B (zh) * 2015-02-11 2020-02-04 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
JP2018507860A (ja) * 2015-02-26 2018-03-22 ザヴァックス ジェネティクス ワクチン カンパニー リミテッドＴｈｅｖａｘ Ｇｅｎｅｔｉｃｓ Ｖａｃｃｉｎｅ Ｃｏ．， Ｌｔｄ． 抗原特異的ｔ細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物
WO2016138618A1 (zh) * 2015-03-02 2016-09-09 成都华创生物技术有限公司 TRAIL穿膜肽样突变体MuR5、制备方法及应用
WO2016138625A1 (zh) * 2015-03-02 2016-09-09 成都华创生物技术有限公司 TRAIL穿膜肽样突变体MuR6、制备方法及应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
CN108026181B (zh) * 2015-10-22 2021-07-02 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
WO2017066962A1 (zh) * 2015-10-22 2017-04-27 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR5S4TR、其制备方法及其应用
EP3402509A4 (en) * 2016-01-14 2019-07-10 Seattle Children's Hospital (DBA Seattle Children's Research Institute) TUMOR SPECIFIC IFNA SECRETION BY CAR T CELLS FOR RESTORING SOLID TUMOR MICRO ENVIRONMENT
CN114028549A (zh) * 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
US11939609B2 (en) 2017-07-24 2024-03-26 The Board Of Trustees Of The Leland Stanford Junior University Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
KR102673699B1 (ko) * 2017-12-13 2024-06-17 이노비오 파마수티컬즈, 인크. Lemd1을 표적화하는 암 백신 및 이의 용도
US20210040469A1 (en) * 2018-01-25 2021-02-11 University Of Washington Engineered cell death-inducing enzymes and methods of use
CN108324692B (zh) * 2018-04-26 2019-09-24 北京爱泰浦生物医药科技有限责任公司 Atap多肽和紫杉醇类药物共晶药及其制备方法和应用
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
CN112243444A (zh) * 2018-06-08 2021-01-19 豪夫迈·罗氏有限公司 具有减少的翻译后修饰的肽接头
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
BR112021008832A2 (pt) * 2018-11-08 2021-08-31 Summation Bio, Inc. Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
CN114746126A (zh) * 2019-10-11 2022-07-12 小利兰·斯坦福大学理事会 用于可调节细胞定位的重组多肽
US12416634B2 (en) * 2020-06-01 2025-09-16 Galderma Holding SA SNAP-25 reporter constructs and methods of using the same
CN113549143B (zh) * 2021-07-21 2022-05-27 吉林大学 一种抗肿瘤多肽Bax-BH3、荧光高分子纳米胶束及其制备方法和应用
CN113717289A (zh) * 2021-07-23 2021-11-30 华东理工大学 一种sac-trail融合蛋白及其制备方法和应用
WO2023031215A2 (en) * 2021-09-02 2023-03-09 Umc Utrecht Holding B.V. Pro-apoptotic construct and use thereof
CN118201636A (zh) * 2021-10-26 2024-06-14 萨摩亚商柏沛生医股份有限公司 抗癌症及感染性疾病的组合疗法
US20240141016A1 (en) * 2021-11-05 2024-05-02 Navicure Biopharmaceuticals Limited Immunogenic fusion proteins against infectious animal diseases
KR20240145409A (ko) * 2023-03-24 2024-10-07 카오티에스 주식회사 신규한 그랜자임 융합단백질 및 이의 용도
CN119656338A (zh) * 2024-12-16 2025-03-21 浙江大学 一种增强T细胞疗效的mRNA药物与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60226816A (ja) 1984-11-16 1985-11-12 Asahi Chem Ind Co Ltd 抗腫瘍活性をもつヒト由来蛋白質
DE3841768A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE60118935D1 (de) 2000-04-24 2006-05-24 Univ Yale New Haven Dna & protein bindende miniatur proteine
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드
RU2409817C2 (ru) 2005-08-16 2011-01-20 Дженентек, Инк. Анализы и способы применения биомаркеров
CN101168742A (zh) * 2007-03-08 2008-04-30 中山大学肿瘤防治中心 一种溶癌病毒及其制备方法
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CN101157729B (zh) * 2007-10-23 2011-01-12 南京大学 一种肿瘤坏死因子相关凋亡配体变体及其应用
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
JP5475766B2 (ja) * 2008-06-30 2014-04-16 ユニバーシティ オブ ペンシルベニア Ｆｎ１４／ＴＲＡＩＬ融合タンパク質
WO2010055929A1 (ja) 2008-11-14 2010-05-20 国立大学法人京都大学 Ｈｓｐ９０を標的にした新規抗がんキメラペプチド

Also Published As

Publication number Publication date
AU2011268876B2 (en) 2014-01-30
IL223640A (en) 2016-05-31
JP2013532972A (ja) 2013-08-22
DK2585480T3 (en) 2015-03-23
CA2800841A1 (en) 2011-12-29
CY1116099T1 (el) 2017-02-08
PH12013500050A1 (en) 2022-10-05
EA023005B1 (ru) 2016-04-29
HK1178908A1 (en) 2013-09-19
RS53851B1 (sr) 2015-08-31
UA111722C2 (uk) 2016-06-10
DK2585480T5 (en) 2015-06-08
KR20130088137A (ko) 2013-08-07
EP2585480B1 (en) 2014-12-10
WO2011161260A1 (en) 2011-12-29
US9102759B2 (en) 2015-08-11
HRP20150241T1 (xx) 2015-06-05
SI2585480T1 (sl) 2015-02-27
US20130164254A1 (en) 2013-06-27
MX2012015246A (es) 2013-02-07
PT2585480E (pt) 2015-03-02
PL391627A1 (pl) 2012-01-02
CN102958940A (zh) 2013-03-06
BR112012032708A2 (pt) 2016-10-11
JP5911481B2 (ja) 2016-04-27
SG186439A1 (en) 2013-01-30
ZA201300677B (en) 2013-09-25
KR101861872B1 (ko) 2018-05-28
AU2011268876A1 (en) 2013-01-10
CA2800841C (en) 2018-07-10
EP2585480A1 (en) 2013-05-01
ES2531288T3 (es) 2015-03-12
EA201291362A1 (ru) 2013-06-28
CN102958940B (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
ZA201300677B (en) Anticancer fusion protein
ZA201404667B (en) Anticancer fusion protein
ZA201303449B (en) Anticancer fusion protein
GB201113558D0 (en) Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung
SG10201500208SA (en) Npp1 fusion proteins
SI2661496T1 (sl) Fuzijski protein proti raku
ZA201405460B (en) Anticancer fusion protein
GB201116180D0 (en) Kraftfahrzeug mit warnsystem
IL226481A0 (en) Enzymes@Maochim
EP2698386B8 (en) Fusion protein
EP2657337A4 (en) FUSION PROTEIN
ZA201308597B (en) Anticancer fusion protein
PL2809342T3 (pl) Peptyd dwufunkcyjny
GB201016494D0 (en) Polypeptide
ZA201207425B (en) Fusion protein
EP2521787A4 (en) IMPROVED PROTEIN EXPRESSION
GB201016346D0 (en) Connection means
PL393146A1 (pl) Przeciwnowotworowe białko fuzyjne
GB201007955D0 (en) Somatosatin fusion proteins
HK1189602A (en) Anticancer fusion protein
GB201010202D0 (en) Fusion polypeptides
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
ZA201301851B (en) Pharmaceutical combinations
GB201104152D0 (en) Fusion Polypeptide